PET/CT scanning with a high HIV/AIDS prevalence

Transfusion and Apheresis Science

Volumn 44, Issue 2, 2011, Pages 167-172

  Warwick, J M ^a   Sathekge, M M ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPH NODE; LYMPHOMA; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; SCINTIGRAPHY; THYMUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM NEOPLASMS; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HIV SEROPOSITIVITY; HUMANS; LIPODYSTROPHY; LYMPH NODES; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; THYMUS GLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952627280     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2011.01.014     Document Type: Article

References (38)

1. UNAIDS, Report on global HIV/AIDS epidemic 2008. UNAIDS; 2008.
2. UNAIDS/WHO Epidemiological fact sheet on HIV, AIDS: South Africa 2008, World Health Organisation, UNAIDS, UNICEF, Geneva, Switzerland.
3. Gallagher B., Fowler J., Gutterson N., et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med 1978, 19:1154-1161.
4. Schiepers C., Filmont J.E., Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl. 1):S82-S88.
5. Isasi C.R., Lu P., Blaufox M.D. A meta analysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005, 104:1066-1074.
6. Zijlstra J.M., Lindauer-van der Werf G., Hoekstra O.S., et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006, 91:522-529.
7. Cheson B.D., Pfistner B., Juweid M.E., et al. International harmonization project on lymphoma revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
8. Brepoels L., Stroobants S., De Wever W., et al. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 2007, 48:1522-1530.
9. Brepoels L., Stroobants S., De Wever W., et al. Hodgkin lymphoma: response assessment by revised international workshop criteria. Leuk Lymphoma 2007, 48:1539-1547.
10. Kirby A.M., Mikhaeel N.G. The role of FDG PET in the management of lymphoma: practical guidelines. Nucl Med Commun 2007, 28:355-357.
11. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003, 14:123-130.
12. Sathekge M., Goethals I., Maes A., et al. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging 2009, 36:1176-1184.
13. Cloyd M.W., Chen J.J., Wang I. How does HIV cause AIDS? The homing theory. Mol Med Today 2000, 6:108-111.
14. Lederman M.M., Margolis L. The lymph node in HIV pathogenesis. Semin Immunol 2008, 20:187-195.
15. Scharko A.M., Perlman S.B., Pyzalski R.W., et al. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003, 362:959-961.
16. Goshen E., Davidson T., Avigdor A., et al. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 2008, 33:610-614.
17. Just P.A., Fieschi C., Baillet G., et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS 2008, 22:695-700.
18. Sathekge M., Maes A., Pottel H., et al. FDG uptake in lymph nodes of 408 HIV and TB patients: implications for cancer staging. Q J Nucl Med Mol Imaging 2010, 54:698-703.
19. Lucignani G., Orunesu E., Cesari M., et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging 2009, 36:640-647.
20. Iyengar S., Chin B., Margolick J.B., et al. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 2003, 362:945-950.
21. Sathekge M., Maes A., Kgomo M., et al. Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count. Nucl Med Commun 2010, 31:137-140.
22. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
23. Behrens G.M., Stoll M., Schmidt R.E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?. Drug Saf 2000, 23:57-76.
24. Bleeker-Rovers C.P., van der Ven A.J., Zomer B., et al. F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS 2004, 18:2430-2432.
25. Sathekge M., Maes A., Kgomo M., et al. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun 2010, 31:311-314.
26. Hardy G., Worrell S., Hayes P., et al. Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection. HIV Med 2004, 5:67-73.
27. Jerushalmi J., Frenkel A., Bar-Shalom R., et al. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment. J Nucl Med 2009, 50:849-853.
28. Samuel R., Bettiker R.L., Suh B. AIDS related opportunistic infections, going but not gone. Arch Pharm Res 2002, 25:215-228.
29. Cadogan M., Dalgleish A.G. HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv Cancer Res 2008, 101:349-395.
30. Aoki Y., Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res 2004, 2:343-349.
31. Cohen P.T., Sande M., Volberding P. Clinical spectrum of HIV disease. The AIDS knowledge base: a textbook of HIV 1994, Little Brown, Boston.
32. Horsburgh C.R. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1332-1338.
33. Liu R.S., Shei H.R., Chu Y.K., et al. Detection of extrapulmonary tuberculosis with F-18 FDG PET. Rev Med Nucl Alasbinm J 2002, 17:504.
34. Sathekge M., Maes A., Kgomo M., et al. Impact of FDG PET on the management of TBC treatment. A pilot study. Nuklearmedizin 2010, 49:35-40.
35. Radin R. HIV infection: analysis in 259 consecutive patients with abnormal abdominal CT findings. Radiology 1995, 197:712-722.
36. Hoffman J.M., Waskin H.A., Schifter T., et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993, 34:567-575.
37. Villringer K., Jäger H., Dichgans M., et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995, 19:532-536.
38. Heald A.E., Hoffman J.M., Bartlett J.A., et al. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996, 7:337-346.